The European Union and AstraZeneca put an end to a bitter dispute over the supply of vaccines

AstraZeneca and the European Union have ended months of bitter legal disputes over vaccine supplies, with an agreement to supply millions of additional doses to the European blockade by early next year.

The deal ends the blame game for the European Union’s slow start to vaccinate its 448 million people, as the US and UK scrambled to secure supplies that would allow them to reopen their economies after a series of blocks.

The pressure on supplies is now over, with the European Union vaccinating 70% of its adults.

AstraZeneca has so far supplied approximately 140 million doses to the European Union. Under the agreement, the pharmaceutical company will have to supply another 20 million doses in this quarter, 75 million by the end of the year and another 65 million in the first quarter of 2022.

An EU executive said in a statement, today, Friday, that the agreement “will increase the total number of doses administered to 300 million doses, as agreed in under the contract “.

The deal ends a legal dispute that has led to discussions of bad faith in a Brussels court at the beginning of quest’year. The court ordered AstraZeneca to administer 50 million doses by September 27 under the threat of a fine of 10 euros ($ 12) for each missed dose.

AstraZeneca said at the time that the court did not insist on prioritizing EU supplies over other contracts.

The company reported liquidation plans in its July quarterly earnings. “Astra does not believe it is mutually beneficial to pursue this lawsuit,” said Rod Dober, executive vice president of AstraZeneca’s biopharmaceutical unit at the time.

“I am very happy that we have managed to reach a common understanding that allows us to move forward and work in collaboration with the European Commission to help overcome the pandemic, “he added.

Read More About: Business News

Leave a Reply